WO1998006411A2 - Use of lactobacillus gg in the rehydrating solution - Google Patents
Use of lactobacillus gg in the rehydrating solution Download PDFInfo
- Publication number
- WO1998006411A2 WO1998006411A2 PCT/IT1997/000201 IT9700201W WO9806411A2 WO 1998006411 A2 WO1998006411 A2 WO 1998006411A2 IT 9700201 W IT9700201 W IT 9700201W WO 9806411 A2 WO9806411 A2 WO 9806411A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diarrhoea
- lactobacillus
- treatment
- acute
- preparation
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 15
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 14
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000001154 acute effect Effects 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001332 colony forming effect Effects 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract description 6
- 235000020932 food allergy Nutrition 0.000 abstract description 6
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 206010016946 Food allergy Diseases 0.000 abstract description 5
- 238000004904 shortening Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 9
- 241000702670 Rotavirus Species 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004916 vomit Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 244000000021 enteric pathogen Species 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QFKWSRIUZIYLCK-UHFFFAOYSA-J copper;disodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide;sulfate Chemical compound [OH-].[Na+].[Na+].[Cu+2].OC([O-])=O.[O-]S([O-])(=O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O QFKWSRIUZIYLCK-UHFFFAOYSA-J 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
Definitions
- the present invention seeks to provide a formulation responsive to such requirements.
- Lactobacillus casei subspecies rhamnosius (so-called also Lactobacillus GG initially isolated from the intestinal bacterial flora of a man) , administered both in the form of powder and yoghurt produced by the fermentation of the milk with said enzyme, is capable of shortening by about 2 days the duration of the diarrhoea in little patients with gastroenteritis by rotavirus which is considered as the most common etiologic agent of acute infant's diarrhoea in the world.
- enteric pathogens Rotavirus and Adenoviru ⁇ of the enteric type (40-41) , Giardia and Cryptosporidium, Salmonella, Shigella, Campylobacter, Yersinia, Aeromonas, E. Coli pathogens (ETEC, EPEC, EHEC, EIEC, EAggEC, searched by specific DNA probes) .
- enteric pathogens Rotavirus and Adenoviru ⁇ of the enteric type (40-41) , Giardia and Cryptosporidium, Salmonella, Shigella, Campylobacter, Yersinia, Aeromonas, E. Coli pathogens (ETEC, EPEC, EHEC, EIEC, EAggEC, searched by specific DNA probes) .
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The early administration of Lactobacillus GG during the rehydrating phase is capable of shortening the duration of the diarrhoea, preventing the following food allergy syndrome in the patient, and promoting a faster weight increase. To this purpose there is provided a preparation to be administered by mouth and formed of an oral rehydrating solution (ORS) of the commercial type, such as Dicodral 60, in which an effective amount of both alive and inactivated ferments Lactobacillus GG is contained.
Description
Treatment of the acute infant's diarrhoea and prevention of allergic reactions to foods swallowed in the following phase bv administering Lactobacillus GG in the oral rehydrating solution
The present invention relates to the treatment of acute infant's diarrhoea and more particularly the early use of the bacterium Lactobacillus GG during the rehydrating phase with the purpose of reducing the duration of the diarrhoea, preventing food allergy syndromes in the patient, and promoting a faster weight recovery.
Acute diarrhoea due in most cases to intestinal infections (gastroenteritis) acquired by orofecal way is still a very important sanitary problem. In fact, 2 to 3 billions of cases of acute diarrhoea occur yearly in the world, such cases causing an estimated mortality of about 5 million infants aged up to five. In Italy and West Europe the mortality due to gastroenteritis has gone progressively and considerably down in recent years and is reduced to 1-10 cases over 100,000 infants/year today. However, also under such circumstances, acute diarrhoea is an event of great importance considering that it is very frequent (recent epidemiological studies in Scandinavia and in Italy show that each infant has, as an average, a little more than one episode/year of acute diarrhoea) . Therefore, direct cost for the treatment and indirect cost due to the absence of the mothers from work are huge. It should not be forgotten that in 4-6% of the cases an acute diarrhoea lasts more than 14 days, thus exposing the infant to the
real risk of developing malnutrition or acquiring food allergies (which actually take place in a large number of cases) , thus inducing further complications and, in the best case, excluding some foods for very long time. As can be seen from the foregoing, it should be very useful to have therapeutical means capable of reducing the duration of the diarrhoetic symptomatology, blocking effectively the possible evolution regarding the food allergy, and improving at the same time the digestion- absorption conditions in order to promote the weight recovery of the little patients.
The present invention seeks to provide a formulation responsive to such requirements.
The current therapy of gastroenteritis is addressed to an unquestionable physiopathologic approach: administering an oral rehydrating solution (ORS) based on a mixture of electrolytes and glucose formulated according to precise requirements so as to promote the intestinal absorption of water and mineral salts and to restore the hydro- electrolytic wealth endangered by diarrhoea. Such an approach, which has been made possible by the knowledge of the physiopathology of the intestinal absorption-digestion processes and has been widely used for the last 10-15 years also in the adult's diarrhoea, has certainly contributed to save many human lives and cannot be questioned at all. However, as well known, it takes no effect on the symptoms, the diarrhoea persisting unchanged, and then is only partially responsive to the above-mentioned requirements.
It is also known that apart from some specific substances the etiologic therapy of the gastroenteritis cannot be carried out as only some bacterial enteric pathogens may be eradicated by a specific therapy accompanied by a shortening of the symptomatology.
In recent years it has been proved (Raza et al., 1995) that a milk enzyme, Lactobacillus casei subspecies rhamnosius (so-called also Lactobacillus GG initially isolated from the intestinal bacterial flora of a man) , administered both in the form of powder and yoghurt produced by the fermentation of the milk with said enzyme, is capable of shortening by about 2 days the duration of the diarrhoea in little patients with gastroenteritis by rotavirus which is considered as the most common etiologic agent of acute infant's diarrhoea in the world. It has been also proved that the administering of such an enzyme has no side-effects at all and is accompanied by an increase of the immunity to rotavirus . Furthermore, it has been thereafter proved that the same product is also capable of thoroughly preventing the increase of the intestinal permeability of the rats caused by the early administering of milk proteins of different species to the growing animals. The latter result is of great importance: it is well known that during an infectious gastroenteritis (that by rotavirus is really the most studied condition) the permeability of the intestinal mucosa is altered by the damage induced by the intestinal infectious process. That such a condition predisposes to the entrance of heterologous food macromolecules and then is capable to initiate a food allergy syndrome in susceptible subjects is an
incontrovertible proof. In fact, it is well supported with documentary evidence that a considerable amount of the allergies to cow's milk afflicting about 3% of the infants came into being after a gastroenteritis.
Starting from such remarks it is assumed that the early administering of Lactobacillus GG during the rehydration phase (i.e. the initial acute diarrhoea treatment phase in which the oral rehydrating solution (ORS) is administered without other foods) can not only further reduce the duration of the diarrhoea (allowing a better and earlier contact of the agent with the damaged intestinal mucosa) but also allow the allergy to food (especially proteins of cow's milk) administered in the following phase to be prevented.
The result of an experimentation carried out on a sample of several little patients proved that a preparation to be administered by mouth and formed of the ferment Lactobacillus GG in a rehydrating solution, identified as the commercial preparation Dicodral 60, in an amount of 100,000 to 1,000,000,000 C.F.U. (Colony Forming Unit) every 500 ml solution, prevents food allergy syndromes besides strongly influencing the duration of the diarrhoea, and allows the weight to be faster recovered.
The effectiveness of administering the above-mentioned preparation is self-evident from the results of the experimentation shown in Tables 1 and 2.
Children aged one to twelve having 4 evacuations/day of liquid faeces for one to some days but not more than 5 days were subjected to test. Criteria for the exclusion
from the test were: preceding treatment with antidiarrhoea products, syndrome of short intestine, associated renal or hepatic diseases, paralytic ileu , chronic inflammatory intestine diseases (Crohn disease, ulcerous rectocolitis) . The test was conducted according to a double-blind method controlled by placebo. The enlisted patients were randomly assigned either to group A assuming Lactobacillus GG (added to the oral rehydrating solution (ORS) Dicodral 60: 10,000,000 C.F.U./250 ml ORS) or to group B assuming placebo (only Dicodral 60) . All patients were rehydrated with said solutions for 6-8 hours and then resumed the usual diet still assuming the oral rehydrating solution until the end of diarrhoea. Furthermore, registry, anthropometric, clinic data of each patient was registered as well as a sample of faeces was taken for the analysis of the following enteric pathogens: Rotavirus and Adenoviruε of the enteric type (40-41) , Giardia and Cryptosporidium, Salmonella, Shigella, Campylobacter, Yersinia, Aeromonas, E. Coli pathogens (ETEC, EPEC, EHEC, EIEC, EAggEC, searched by specific DNA probes) . Finally, analysis were carried out on the following parameters which were registered at the beginning and at periodic intervals during the analysis: body weight, defecation (frequency and quality) , total duration of diarrhoea, oral feeding and complications such as vomit and intolerance to carbohydrates (the latter searched daily by Clinitest) .
RESULTS Data relates to 32 patients, 17 in group A, 15 in group B. Both groups were comparable in age, weight, and duration of diarrhoea at the admission (table 1) . The medium age was 23.9 months (range: 2-61) in group A, 25.2 months
(range: 3-96) in group B. At the admission diarrhoea was lasting on the average from 2.9 days (range: 1-5) in group
A, 2.6 days (range: 1-4) in group B. The mean duration of diarrhoea from the beginning of the treatment was 1.3 days (range 1-3) in group A, and 1.4 days (range 1-3) in group
B. The mean duration of diarrhoea from the beginning of the treatment could be estimated in hours for 15 patients: it was 17.1 hours (range: 4-34) in group A, and 27 hours (range: 6-70) in group B (table 2) . The mean number of liquid evacuations in the two days of evaluation was 5.6 faecal discharges (range 1-11) in group A and 7.3 faecal discharges (range 1-24) in group B. The mean weight increase was always greater in group A in all of the evaluation days as shown in the diagram. Among the complications, vomit was present in 17.6% of group A and 20% of group B; the intolerance of lactose was present in 5.8% of group A and 6.6% of group B. Finally, among the isolated pathogens, Rotavirus was isolated in 11.76% of group A and 6.6% of group B. The results of the experiments have to be considered as preliminary, however, they allow as from now some salient points to be pointed out:
Lactobacillus GG administered by mouth in the oral rehydrating solution has proved to be well tolerated and did not result in any intolerance or side effects.
The duration of an acute diarrhoea tends to be shorter in the treated patients than in the controls, especially if the duration is expressed in hours; however, the dispersion of the values and the little number of cases do not allow yet to confirm such a statement according to a statistic validation.
The most interesting data, however, is the faster weight increase of the infants assuming the ferment than the controls. As the latter data relates to the first 24 hours of observation, it is of course sign of a more effective rehydration and/or re-nourishing. One could then suppose that the treated patients markedly improve their digestion conditions after a few hours administration with the consequence of a faster restoration of the hydro- electrolytic wealth. Table 1.- Observation Data
Group A Group B P
1-GG (n=17) Placebo (n=15) N.S.
Age (month) 23.9 (2-61) 25.2 (3-96) N.S.
Weight (g) 11841 ± 6250 13439 ± 6700 N.S.
Undernouriεhed 2 (12%) 2 (13%) N.S.
No dehydration 7% 7% N.S.
Dehydration < 5% 93% 93% N.S.
Dehydration 5-10% - 14% N.S.
Dehydration > 10% N.S.
Duration of the diarrhoea (days) 2.9 ± 0.7 2.6 ± 1.1 N.S.
Rotavirus diarrhoea 2 (11.76%) 1 (6.6%) N.S.
Table 2.- Clinic Course
Group A (n=17] Group B (n=15)
Vomit (%) 3 (17.64%) 3 (20%)
Intolerance to lactose 1 (5.88%) 1 (6.64%) Duration of diarrhoea from the beginning of 1.33 days 1.46 days the treatment range (1-3) range (1-3)
Group A (n=9) Group B (n=6)
Duration of diarrhoea from the beginning of 17.1 hours 27 hours the treatment range (4-34) range (6-70)
As can be seen, the product of the present invention may then find application in the acute infant's diarrhoea, in the infectious infant's gastroenteritis, in the therapy and prevention of the infant's protracted diarrhoea syndrome as well as in the prevention of the allergy to cow's milk caused by gastroenteritis.
Claims
1. Use of an effective amount of both alive and inactivated ferments Lactobacillus GG in the oral rehydrating solution (ORS) for the early treatment of the acute infant's diarrhoea of a variety of aetiologies.
2. A preparation to be administered by mouth for the treatment of the acute infant's diarrhoea which is formed of a rehydrating solution (ORS) containing an effective amount of both alive and inactivated Lactobacillus GG.
3. A preparation to be administered by mouth for the treatment of the acute infant's diarrhoea which is formed of a rehydrating solution (ORS) containing an amount of both alive and inactivated Lactobacillus GG between 100,000 and 1,000,000,000 C.F.U. (Colony Forming Units) every 500 ml solution.
4. The preparation to be administered by mouth for the treatment of the acute infant's diarrhoea of the preceding claim, wherein the rehydrating solution (ORS) is identified by the commercial preparation Dicodral 60.
5. A preparation to be administered by mouth for the treatment of the acute infant's diarrhoea of claim 4, wherein the amount of Lactobacillus GG is 10,000,000 C.F.U. every 250 ml Dicodral 60.
6. A preparation to be administered by mouth for the treatment of the acute infant's diarrhoea of claims from 2 on, wherein it reduces the duration of the diarrhoea, prevents allergies to foods swallowed in the following phase, and allows a faster weight increase.
7. A method for the treatment of acute infant's diarrhoea, the prevention of allergies to foods swallowed in the following phase and a faster weight increase, wherein there is provided the early administration of Lactobacillus GG in the initial phase of treatment of the acute diarrhoea by adding it to the oral rehydrating solution (ORS) .
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97935765A EP0918531A2 (en) | 1996-08-09 | 1997-08-04 | Use of lactobacillus gg in rehydrating solution |
| AU38639/97A AU3863997A (en) | 1996-08-09 | 1997-08-04 | Treatment of the acute infant's diarrhoea and prevention of allergic reactions to foods swallowed in the following phase by administering lactobacillus gg in the oral rehydrating solution |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM96A000571 | 1996-08-09 | ||
| IT96RM000571A IT1284877B1 (en) | 1996-08-09 | 1996-08-09 | TREATMENT OF ACUTE DIARRHEA IN CHILDREN AND PREVENTION OF ALLERGIC SENSITIZATION TO FOODS INTRODUCED DURING THE PHASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998006411A2 true WO1998006411A2 (en) | 1998-02-19 |
| WO1998006411A3 WO1998006411A3 (en) | 1998-05-07 |
Family
ID=11404390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IT1997/000201 WO1998006411A2 (en) | 1996-08-09 | 1997-08-04 | Use of lactobacillus gg in the rehydrating solution |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0918531A2 (en) |
| AU (1) | AU3863997A (en) |
| IT (1) | IT1284877B1 (en) |
| WO (1) | WO1998006411A2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1034787A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| EP1034788A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| WO2000053202A1 (en) * | 1999-03-11 | 2000-09-14 | Societe Des Produits Nestle S.A. | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
| WO2001095741A1 (en) * | 2000-06-13 | 2001-12-20 | Unilever N.V. | Non-viable lactobacillus containing food product |
| US7183108B1 (en) | 1998-11-18 | 2007-02-27 | Compagnie Gervais Danone | Selection and uses of lactic acid bacteria strains modulating non-specific immunity |
| ES2277550A1 (en) * | 2005-12-21 | 2007-07-01 | Laboratorios Casen-Fleet, S.L. | Pharmaceutical kit for a preparation of a hydration salt with probiotic for babies |
| WO2012062781A1 (en) * | 2010-11-11 | 2012-05-18 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0199535A2 (en) * | 1985-04-17 | 1986-10-29 | Sherwood L. Gorbach | Lactobacillus acidophilus strains of bacteria and compositions thereof |
| EP0271364A2 (en) * | 1986-12-12 | 1988-06-15 | Biorem C.C. | Preparation suitable for treating enteric disorders |
| WO1991015199A1 (en) * | 1990-04-09 | 1991-10-17 | Medicis Corporation | Antidiarrheal composition and method |
| WO1994018997A1 (en) * | 1993-02-24 | 1994-09-01 | Valio Ltd. | Method of enhancing immune response to oral vaccines |
| US5413785A (en) * | 1993-01-27 | 1995-05-09 | New England Deaconess Hospital Corp. | Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo |
-
1996
- 1996-08-09 IT IT96RM000571A patent/IT1284877B1/en active IP Right Grant
-
1997
- 1997-08-04 WO PCT/IT1997/000201 patent/WO1998006411A2/en not_active Application Discontinuation
- 1997-08-04 EP EP97935765A patent/EP0918531A2/en not_active Withdrawn
- 1997-08-04 AU AU38639/97A patent/AU3863997A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0199535A2 (en) * | 1985-04-17 | 1986-10-29 | Sherwood L. Gorbach | Lactobacillus acidophilus strains of bacteria and compositions thereof |
| EP0271364A2 (en) * | 1986-12-12 | 1988-06-15 | Biorem C.C. | Preparation suitable for treating enteric disorders |
| WO1991015199A1 (en) * | 1990-04-09 | 1991-10-17 | Medicis Corporation | Antidiarrheal composition and method |
| US5413785A (en) * | 1993-01-27 | 1995-05-09 | New England Deaconess Hospital Corp. | Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo |
| WO1994018997A1 (en) * | 1993-02-24 | 1994-09-01 | Valio Ltd. | Method of enhancing immune response to oral vaccines |
Non-Patent Citations (4)
| Title |
|---|
| A. R. PANT ET AL.: "LACTOBACILLUS GG AND ACUTE DIARRHOEA IN YOUNG CHILDREN IN THE TROPICS." JOURNAL OF TROPICAL PEDIATRICS, vol. 42, no. 3, June 1996, pages 162-165, XP002058046 * |
| HELI MAJAMAA ET AL.: "LACTIC ACID BACTERIA IN THE TREATMENT OF ACUTE ROTAVIRUS GASTROENTERITIS." JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol. 20, no. 3, April 1995, pages 333-338, XP002058047 * |
| MINNA KAILA ET AL: "NUTRITIONAL MANAGEMENT OF ACUTE DIARRHEA" NUTRITION TODAY, vol. 31, no. 6, November 1996 - December 1996, pages 16S-18S, XP002058044 * |
| MINNA KAILA ETAL.: "VIABLE VERSUS INACTIVATED LACTOBACILLUS STRAIN GG IN ACUTE ROTAVIRUS DIARRHOEA." ARCHIVES OF DISEASE IN CHILDHOOD, vol. 72, no. 1, January 1995, pages 51-53, XP002058045 * |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183108B1 (en) | 1998-11-18 | 2007-02-27 | Compagnie Gervais Danone | Selection and uses of lactic acid bacteria strains modulating non-specific immunity |
| US6835376B1 (en) | 1999-03-11 | 2004-12-28 | Nestec S.A. | Lactobacillus paracasei strain for preventing diarrhea caused by pathogenic bacteria |
| US7029669B1 (en) | 1999-03-11 | 2006-04-18 | Nestec S. A. | Lactic acid bacteria strains capable of preventing diarrhoea |
| AU779789B2 (en) * | 1999-03-11 | 2005-02-10 | Societe Des Produits Nestle S.A. | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
| WO2000053201A1 (en) * | 1999-03-11 | 2000-09-14 | Societe Des Produits Nestle S.A. | Lactic acid bacteria strains capable of preventing diarrhoea |
| AU779804B2 (en) * | 1999-03-11 | 2005-02-10 | Societe Des Produits Nestle S.A. | Lactic acid bacteria strains capable of preventing diarrhoea |
| EP1415656A1 (en) * | 1999-03-11 | 2004-05-06 | Société des Produits Nestlé S.A. | Lactobacillus strains capable of preventing diarrhoea caused by rotaviruses |
| EP1034788A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| US6887465B1 (en) | 1999-03-11 | 2005-05-03 | Nestec S.A. | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
| WO2000053200A1 (en) * | 1999-03-11 | 2000-09-14 | Societe Des Produits Nestle S.A. | Lactobacillus strains preventing diarrhoea pathogenic bacteria |
| WO2000053202A1 (en) * | 1999-03-11 | 2000-09-14 | Societe Des Produits Nestle S.A. | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
| EP1034787A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| WO2001095741A1 (en) * | 2000-06-13 | 2001-12-20 | Unilever N.V. | Non-viable lactobacillus containing food product |
| AU2001269015B2 (en) * | 2000-06-13 | 2004-10-14 | Unilever Plc | Non-viable lactobacillus containing food product |
| ES2277550A1 (en) * | 2005-12-21 | 2007-07-01 | Laboratorios Casen-Fleet, S.L. | Pharmaceutical kit for a preparation of a hydration salt with probiotic for babies |
| WO2012062781A1 (en) * | 2010-11-11 | 2012-05-18 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
| EP2455094A1 (en) * | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
| US9345728B2 (en) | 2010-11-11 | 2016-05-24 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3863997A (en) | 1998-03-06 |
| IT1284877B1 (en) | 1998-05-22 |
| ITRM960571A0 (en) | 1996-08-09 |
| ITRM960571A1 (en) | 1998-02-09 |
| WO1998006411A3 (en) | 1998-05-07 |
| EP0918531A2 (en) | 1999-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0923293B1 (en) | Treatment of diarrhea | |
| Wheeler et al. | Vibrionic enteritis in infants | |
| Fuller | Probiotics in human medicine. | |
| RU2332224C1 (en) | APPLICATION OF THERAPEUTICALLY EFFECTIVE QUANTITY OF Bb-12 AND LGG FOR PRODUCTION OF CURING OR RESPIRATORY INFECTION AND ACUTE MEDIA OTITIS PREVENTING MEDIUM FOR BABIES | |
| Salminen et al. | Lactic acid bacteria in the gut in normal and disordered states | |
| US5340577A (en) | Probiotic for control of salmonella | |
| WO2020197188A1 (en) | Kimchi lactic acid bacteria lactobacillus sakei wikim0109 having efficacy for relief of arthritis | |
| EP1162987A1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
| Gonzalez et al. | Biotherapeutic role of fermented milk | |
| EP0203586A2 (en) | A composition for treating gastrointestinal disease in animals | |
| CN114390897A (en) | Composition of prebiotics and probiotics and application thereof | |
| EP0918531A2 (en) | Use of lactobacillus gg in rehydrating solution | |
| Duval‐Iflah et al. | Effects of racecadotril and loperamide on bacterial proliferation and on the central nervous system of the newborn gnotobiotic piglet | |
| US3988440A (en) | Remedy for treating gastritis, gastric and duodenal ulcers | |
| JP2004051530A (en) | Intestinal flora-improving agent and food or drink containing the same | |
| WO2011107960A1 (en) | Compositions comprising lactobacillus mucosae for medical use | |
| WO2020040450A1 (en) | Composition for prevention or treatment of behcet's disease or herpes simplex virus infection comprising eubacterium rectale | |
| Black et al. | Mecillinam, a new prophylactic for travellers' diarrhoea: a prospective double-blind study in tourists travelling to Egypt and the Far East | |
| Tanaka | Clinical effects of bifidobacteria and lactobacilli | |
| RU2198673C2 (en) | Medicinal preparation for optimization of mucus viscosity and stimulation of intestine function | |
| EP3810161A1 (en) | Non-viable bifidobacterium bifidum bacteria and uses thereof | |
| KR19980081625A (en) | Prevention and treatment of infections caused by intestinal hemorrhagic E. coli | |
| JP2004135669A (en) | Lactic bacterium strain producing active antibacterial for preventing growth of helicobacter pylori and listeria monocytogenes and named pediococcus pentosaceus ctb-8, method for producing antibacterial with antibacterial characteristic by using same and method for using the antibacterial of live bacterium agent as functional food and pharmaceutical | |
| JP2004135669A6 (en) | A lactic acid bacterial strain named Pediococcus pentosaceus CBT-8, which produces an antibacterial active substance that suppresses the growth of Helicobacter pylori and Listeria monocytogenes, is used as an antibacterial bacterium. Method for producing antibacterial substance having bioactive agent and method for utilizing antibacterial substance for functional foods and pharmaceuticals | |
| EP1133991B1 (en) | Bacteriostatic compositions for salmonellae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 09230719 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997935765 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997935765 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998509565 Format of ref document f/p: F |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997935765 Country of ref document: EP |